UNIQURE NV (QURE) Fundamental Analysis & Valuation

NASDAQ:QURE • NL0010696654

12.47 USD
+1.82 (+17.09%)
Last: Mar 6, 2026, 10:30 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This QURE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

QURE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. The financial health of QURE is average, but there are quite some concerns on its profitability. QURE is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. QURE Profitability Analysis

1.1 Basic Checks

  • In the past year QURE has reported negative net income.
  • In the past year QURE has reported a negative cash flow from operations.
  • In the past 5 years QURE reported 4 times negative net income.
  • QURE had negative operating cash flow in 4 of the past 5 years.
QURE Yearly Net Income VS EBIT VS OCF VS FCFQURE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M

1.2 Ratios

  • With a decent Return On Assets value of -24.12%, QURE is doing good in the industry, outperforming 71.15% of the companies in the same industry.
  • QURE has a Return On Equity (-100.04%) which is in line with its industry peers.
Industry RankSector Rank
ROA -24.12%
ROE -100.04%
ROIC N/A
ROA(3y)-34.75%
ROA(5y)-16.3%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
QURE Yearly ROA, ROE, ROICQURE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1K 2K 3K

1.3 Margins

  • The Gross Margin of QURE (89.53%) is better than 91.35% of its industry peers.
  • In the last couple of years the Gross Margin of QURE has declined.
  • QURE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.53%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.57%
GM growth 5YN/A
QURE Yearly Profit, Operating, Gross MarginsQURE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. QURE Health Analysis

2.1 Basic Checks

  • QURE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, QURE has more shares outstanding
  • The number of shares outstanding for QURE has been increased compared to 5 years ago.
  • Compared to 1 year ago, QURE has an improved debt to assets ratio.
QURE Yearly Shares OutstandingQURE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
QURE Yearly Total Debt VS Total AssetsQURE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of -1.48, we must say that QURE is in the distress zone and has some risk of bankruptcy.
  • QURE's Altman-Z score of -1.48 is in line compared to the rest of the industry. QURE outperforms 52.88% of its industry peers.
  • A Debt/Equity ratio of 2.63 is on the high side and indicates that QURE has dependencies on debt financing.
  • QURE has a Debt to Equity ratio of 2.63. This is in the lower half of the industry: QURE underperforms 79.04% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.63
Debt/FCF N/A
Altman-Z -1.48
ROIC/WACCN/A
WACC6.01%
QURE Yearly LT Debt VS Equity VS FCFQURE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 10.43 indicates that QURE has no problem at all paying its short term obligations.
  • The Current ratio of QURE (10.43) is better than 81.92% of its industry peers.
  • A Quick Ratio of 10.43 indicates that QURE has no problem at all paying its short term obligations.
  • The Quick ratio of QURE (10.43) is better than 81.92% of its industry peers.
Industry RankSector Rank
Current Ratio 10.43
Quick Ratio 10.43
QURE Yearly Current Assets VS Current LiabilitesQURE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. QURE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 30.30% over the past year.
  • Looking at the last year, QURE shows a very negative growth in Revenue. The Revenue has decreased by -40.64% in the last year.
  • QURE shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -15.56% yearly.
EPS 1Y (TTM)30.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.16%
Revenue 1Y (TTM)-40.64%
Revenue growth 3Y-46.73%
Revenue growth 5Y-15.56%
Sales Q2Q%6.68%

3.2 Future

  • The Earnings Per Share is expected to grow by 30.22% on average over the next years. This is a very strong growth
  • QURE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 122.75% yearly.
EPS Next Y-0.18%
EPS Next 2Y16.97%
EPS Next 3Y29.98%
EPS Next 5Y30.22%
Revenue Next Year132.5%
Revenue Next 2Y239.24%
Revenue Next 3Y182.61%
Revenue Next 5Y122.75%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
QURE Yearly Revenue VS EstimatesQURE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
QURE Yearly EPS VS EstimatesQURE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

1

4. QURE Valuation Analysis

4.1 Price/Earnings Ratio

  • QURE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year QURE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QURE Price Earnings VS Forward Price EarningsQURE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QURE Per share dataQURE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • QURE's earnings are expected to grow with 29.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.97%
EPS Next 3Y29.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. QURE Dividend Analysis

5.1 Amount

  • No dividends for QURE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

QURE Fundamentals: All Metrics, Ratios and Statistics

UNIQURE NV

NASDAQ:QURE (3/6/2026, 10:30:07 AM)

12.47

+1.82 (+17.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-02
Earnings (Next)N/A
Inst Owners91.11%
Inst Owner Change8.02%
Ins Owners1.48%
Ins Owner Change-0.63%
Market Cap776.76M
Revenue(TTM)16.10M
Net Income(TTM)-198.97M
Analysts80.91
Price Target51.51 (313.07%)
Short Float %18.45%
Short Ratio3.94
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.21%
Min EPS beat(2)-50.39%
Max EPS beat(2)41.97%
EPS beat(4)3
Avg EPS beat(4)8.99%
Min EPS beat(4)-50.39%
Max EPS beat(4)41.97%
EPS beat(8)5
Avg EPS beat(8)-10.88%
EPS beat(12)5
Avg EPS beat(12)-37.07%
EPS beat(16)8
Avg EPS beat(16)-18.94%
Revenue beat(2)1
Avg Revenue beat(2)-12.93%
Min Revenue beat(2)-30.8%
Max Revenue beat(2)4.94%
Revenue beat(4)1
Avg Revenue beat(4)-27.83%
Min Revenue beat(4)-75.51%
Max Revenue beat(4)4.94%
Revenue beat(8)3
Avg Revenue beat(8)-19.73%
Revenue beat(12)4
Avg Revenue beat(12)-34.69%
Revenue beat(16)5
Avg Revenue beat(16)-19.08%
PT rev (1m)-5.04%
PT rev (3m)-12.52%
EPS NQ rev (1m)-0.71%
EPS NQ rev (3m)-1.67%
EPS NY rev (1m)-0.08%
EPS NY rev (3m)-15.21%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-11.8%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)-14.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 48.25
P/FCF N/A
P/OCF N/A
P/B 3.91
P/tB 7.71
EV/EBITDA N/A
EPS(TTM)-3.45
EYN/A
EPS(NY)-3.46
Fwd EYN/A
FCF(TTM)-2.86
FCFYN/A
OCF(TTM)-2.86
OCFYN/A
SpS0.26
BVpS3.19
TBVpS1.62
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -24.12%
ROE -100.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.53%
FCFM N/A
ROA(3y)-34.75%
ROA(5y)-16.3%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.57%
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 2.63
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.97%
Cap/Sales 2.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.43
Quick Ratio 10.43
Altman-Z -1.48
F-Score5
WACC6.01%
ROIC/WACCN/A
Cap/Depr(3y)29.91%
Cap/Depr(5y)107.27%
Cap/Sales(3y)20.1%
Cap/Sales(5y)16.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.16%
EPS Next Y-0.18%
EPS Next 2Y16.97%
EPS Next 3Y29.98%
EPS Next 5Y30.22%
Revenue 1Y (TTM)-40.64%
Revenue growth 3Y-46.73%
Revenue growth 5Y-15.56%
Sales Q2Q%6.68%
Revenue Next Year132.5%
Revenue Next 2Y239.24%
Revenue Next 3Y182.61%
Revenue Next 5Y122.75%
EBIT growth 1Y-4.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.18%
EBIT Next 3Y9.43%
EBIT Next 5Y37.02%
FCF growth 1Y4.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.61%
OCF growth 3YN/A
OCF growth 5YN/A

UNIQURE NV / QURE FAQ

Can you provide the ChartMill fundamental rating for UNIQURE NV?

ChartMill assigns a fundamental rating of 3 / 10 to QURE.


What is the valuation status for QURE stock?

ChartMill assigns a valuation rating of 1 / 10 to UNIQURE NV (QURE). This can be considered as Overvalued.


What is the profitability of QURE stock?

UNIQURE NV (QURE) has a profitability rating of 2 / 10.


How financially healthy is UNIQURE NV?

The financial health rating of UNIQURE NV (QURE) is 4 / 10.


What is the expected EPS growth for UNIQURE NV (QURE) stock?

The Earnings per Share (EPS) of UNIQURE NV (QURE) is expected to decline by -0.18% in the next year.